Farshid Dayyani, MD, PhD

• Gastrointestinal Cancer Services
• Colorectal Disease Services
• Esophageal Disease Services
• Liver Cancer Services
• Pancreas Cancer Services
• Medical Oncology Services
• Hematology Oncology Services

• American Board of Internal Medicine, Internal Medicine
• American Board of Internal Medicine, Medical Oncology

• English
• German
• Farsi

• Professor — Division of Hematology/Oncology, Department of Medicine, UCI School of Medicine
• Medical Director — Stern Center for Cancer Clinical Trials & Research, UCI Health Chao Family Comprehensive Cancer Center
• Member — American Society of Clinical Oncology (ASCO)
• Member — Medical Oncology Association of Southern California (MOASC)

• Physicians of Excellence, Orange County Medical Association — 2022-2023
• ASCO Cancer Foundation Merit Award, Genitourinary Cancers Symposium
• American Society of Hematology Annual Meeting Travel Award
• Clifton D. Howe Award for Clinical Excellence, MD Anderson Cancer Center
• Achievement in Basic Science Fellowship Award 2011, MD Anderson Cancer Center
• Trainee Excellence Award, MD Anderson Cancer Center
• ASCO Young Investigator Award — 2010
• Prostate Cancer Foundation Young Investigator Award — 2011

Dr. Farshid Dayyani is a board-certified UCI Health medical oncologist who specializes in the treatment of gastrointestinal and hepatobiliary malignancies. His clinical interests include colorectal, stomach and esophageal cancers, anal carcinoma, liver and pancreatic cancer.

Dayyani earned his medical degree at Ludwig Maximilian University of Munich in Germany, where he also received a doctoral degree in immunology. Next, he completed a research fellowship in cancer biology at Harvard University in Boston, Mass, followed by a residency in internal medicine at Beth Israel Deaconess Medical Center in Boston, a teaching hospital of Harvard Medical School. He also completed a fellowship in medical oncology at the University of Texas MD Anderson Cancer Center in Houston.

His research focus is on gastrointestinal and hepatobiliary malignancies. His goal is to bring leading-edge treatments to patients with gastrointestinal cancers through innovative clinical trials and translational research. He is the author or co-author of more than 40 research papers published in leading medical journals.

Dayyani, who also speaks German and Farsi, sees patients at the UCI Health Chao Family Comprehensive Cancer Center and UCI Health Cancer Center — Newport.